The discovery of stem cells by researchers in the late 1990s quickly aroused the interest of a large number of medical researchers due to the two characteristics of self-replicating ability and multi-directional differentiation potential of stem cells, and people once pinned their hopes on this miraculous cell and expected to find new ways to cure the disease in the future. However, at this stage, there are still many unconquered difficulties in the treatment of Parkinson’s disease with stem cells, and they are still very far from clinical application. General knowledge of stem cells There are three general sources of stem cells: embryonic stem cells, mature stem cells (e.g. bone marrow) and mature somatic cells (e.g. muscle, skin, etc.). Among them, mature somatic cells are the result of recent scientific research, which can avoid the ethical problems caused by the use of embryonic stem cells, and this will be a very big contribution to the scientific development of stem cells. The main directions of stem cell research (including basic and clinical research), there are five main directions: the establishment of viral models, drug toxicology analysis, the development of new drugs, gene therapy and stem cell transplantation. Of these, stem cell transplantation is again well known to us. The main movement disorder diseases that stem cells are used for research are Parkinson’s disease, multiple system atrophy, Huntington’s chorea, etc. Can stem cells treat Parkinson’s disease in the future? Since the exact mechanism of Parkinson’s disease development is not well understood, there is still no definite and effective way to stop the onset and progression of Parkinson’s disease so far. At this stage, drug therapy and deep brain electrical stimulation (also known as DBS and pacemakers) are mainly symptomatic treatments to control and improve symptoms, although there is some evidence in the literature that DBS has a protective effect on the course of Parkinson’s disease. In recent studies, it has been found that the brain, which has been thought to have no regenerative capacity, also has the ability to repair and regenerate itself; this provides a stronger basis to support stem cell transplantation or gene therapy for Parkinson’s disease. Scientists have found that there are “dormant” nerve cells in the adult brain that, when activated, can differentiate into functional neurons and can be integrated into existing neural networks. Additional evidence also suggests that such cells may be present in the substantia nigra of the brain, and it would be interesting to find out if the substantia nigra of Parkinson’s patients is deactivated. neurons and how such regenerating neurons establish a balanced relationship, then a cure for Parkinson’s disease would no longer be a luxury. With the continuous progress and breakthroughs in stem cell research, the author believes that stem cells offer a possibility for the treatment of Parkinson’s disease. It is important to note that at this stage, the expectation can only be limited to “possible” because the current research has not shown any clear conclusions. Current advances in stem cell research in Parkinson’s 1. Only one clinical trial of stem cell therapy for Parkinson’s disease was reported in 2002, which resulted in a slight improvement in symptoms, but caused strong allodynia and very unsatisfactory results. 2.The other official literature reports are all animal experimental studies, including stem cell transplantation, gene therapy, stem cell differentiation, etc. 3.Although some people have mentioned on some occasions that stem cell therapy for Parkinson’s has achieved some results, we question the authenticity of these sporadic reports. The reasons are as follows: firstly, there is no official literature report, and its objectivity and impartiality are questioned; secondly, there is no strict experimental control; thirdly, some people question the time that the neural cells transplanted by these so-called transplantation methods can survive. 4, China’s health administration has so far not approved the use of stem cells for the treatment of Parkinson’s disease, and in 2012, the former Ministry of Health (now renamed as the National Health and Planning Commission, or the Health and Planning Commission) and the State Food and Drug Administration’s Leading Group for the Rectification of Stem Cell Clinical Research and Application Norms, organized an expert committee to study and develop a series of management norms related to stem cells, which have been formed The draft was solicited for comments and was made available for national consultation in March 2013. Conclusion Although stem cell research has made great progress and offers a possibility for the treatment of Parkinson’s disease. However, its application is still controversial and there are still many technical hurdles to overcome: for example, whether transplantation will cause tumors, whether it will produce rejection reactions, whether it can establish connections with functional areas of the brain, and so on. Among the thousands of cells transplanted, it only takes one stem cell to go wrong to bring the possibility of tumor to the patient. So stem cell research will take longer than other medical research to validate the results. Therefore, it is important that patients with Parkinson’s disease do not become ill in the process of seeking treatment at this time. Stem cell research for Parkinson’s disease still needs to overcome countless hurdles, and we should also remain sensible about future scientific expectations, after all, the primary principle of medical treatment is the principle of not causing any harm to people.